Which has preferable valuation & earnings, CPRX or EVO?

Catalyst Pharmaceuticals has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Catalyst Pharmaceuticals $588.99M 6.53 $214.33M $1.74 18.06 Evotec $891.97M 1.07 -$117.12M N/A N/A

Does the media refer more to CPRX or EVO?

In the previous week, Catalyst Pharmaceuticals and Catalyst Pharmaceuticals both had 1 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 0.00 equaled Evotec'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, EVO or CRNX?

Evotec has higher revenue and earnings than Crinetics Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 1.07 -$117.12M N/A N/A Crinetics Pharmaceuticals $7.70M 495.43 -$465.32M -$5.13 N/A

Does the media refer more to EVO or CRNX?

In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Crinetics Pharmaceuticals and 1 mentions for Evotec. Crinetics Pharmaceuticals' average media sentiment score of 0.57 beat Evotec's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ACAD or EVO?

ACADIA Pharmaceuticals has higher revenue and earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ACADIA Pharmaceuticals $1.07B 3.73 $391M $2.20 10.62 Evotec $891.97M 1.07 -$117.12M N/A N/A

Does the media favor ACAD or EVO?

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Evotec. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 1 mentions for Evotec. ACADIA Pharmaceuticals' average media sentiment score of 0.75 beat Evotec's score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, EVO or OGN?

Organon & Co. has higher revenue and earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 1.07 -$117.12M N/A N/A Organon & Co. $6.16B 0.57 $187M $0.93 14.48

Is EVO or OGN more profitable?

Organon & Co. has a net margin of 3.99% compared to Evotec's net margin of -26.20%. Organon & Co.'s return on equity of 99.95% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Organon & Co. 3.99% 99.95% 6.22%

Does the media refer more to EVO or OGN?

In the previous week, Organon & Co. had 5 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Organon & Co. and 1 mentions for Evotec. Organon & Co.'s average media sentiment score of 0.28 beat Evotec's score of 0.00 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Organon & Co. 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, NAMS or EVO?

Evotec has higher revenue and earnings than NewAmsterdam Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewAmsterdam Pharma $22.57M 168.92 -$203.82M -$1.79 N/A Evotec $891.97M 1.07 -$117.12M N/A N/A

Evotec (EVO) Competitors

$2.69 +0.07 (+2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$2.68 0.00 (-0.19%)

As of 04:10 PM Eastern

Compare

EVO vs. CPRX, CRNX, ACAD, OGN, and NAMS

Should you buy Evotec stock or one of its competitors? MarketBeat compares Evotec with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evotec include Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), ACADIA Pharmaceuticals (ACAD), Organon & Co. (OGN), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

How does Evotec compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Catalyst Pharmaceuticals and Catalyst Pharmaceuticals both had 1 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 0.00 equaled Evotec'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evotec	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Evotec has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Evotec's net margin of -26.20%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Evotec	-26.20%	-24.93%	-11.35%

Catalyst Pharmaceuticals has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.53	$214.33M	$1.74	18.06
Evotec	$891.97M	1.07	-$117.12M	N/A	N/A

Catalyst Pharmaceuticals presently has a consensus price target of $32.00, indicating a potential upside of 1.85%. Evotec has a consensus price target of $7.00, indicating a potential upside of 160.22%. Given Evotec's higher probable upside, analysts clearly believe Evotec is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Catalyst Pharmaceuticals beats Evotec on 9 of the 13 factors compared between the two stocks.

How does Evotec compare to Crinetics Pharmaceuticals?

Evotec (NASDAQ:EVO) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Evotec currently has a consensus target price of $7.00, suggesting a potential upside of 160.22%. Crinetics Pharmaceuticals has a consensus target price of $76.13, suggesting a potential upside of 110.41%. Given Evotec's higher probable upside, equities research analysts plainly believe Evotec is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Evotec has a net margin of -26.20% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Evotec's return on equity of -24.93% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

Evotec has higher revenue and earnings than Crinetics Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	1.07	-$117.12M	N/A	N/A
Crinetics Pharmaceuticals	$7.70M	495.43	-$465.32M	-$5.13	N/A

Evotec has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Crinetics Pharmaceuticals and 1 mentions for Evotec. Crinetics Pharmaceuticals' average media sentiment score of 0.57 beat Evotec's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.8% of Evotec shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Crinetics Pharmaceuticals beats Evotec on 8 of the 15 factors compared between the two stocks.

How does Evotec compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Evotec's net margin of -26.20%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Evotec	-26.20%	-24.93%	-11.35%

ACADIA Pharmaceuticals presently has a consensus target price of $31.63, suggesting a potential upside of 35.38%. Evotec has a consensus target price of $7.00, suggesting a potential upside of 160.22%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

ACADIA Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Evotec has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Evotec. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 1 mentions for Evotec. ACADIA Pharmaceuticals' average media sentiment score of 0.75 beat Evotec's score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has higher revenue and earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.73	$391M	$2.20	10.62
Evotec	$891.97M	1.07	-$117.12M	N/A	N/A

Summary

ACADIA Pharmaceuticals beats Evotec on 12 of the 14 factors compared between the two stocks.

How does Evotec compare to Organon & Co.?

Evotec (NASDAQ:EVO) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Organon & Co. has higher revenue and earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	1.07	-$117.12M	N/A	N/A
Organon & Co.	$6.16B	0.57	$187M	$0.93	14.48

Organon & Co. has a net margin of 3.99% compared to Evotec's net margin of -26.20%. Organon & Co.'s return on equity of 99.95% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Organon & Co.	3.99%	99.95%	6.22%

In the previous week, Organon & Co. had 5 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Organon & Co. and 1 mentions for Evotec. Organon & Co.'s average media sentiment score of 0.28 beat Evotec's score of 0.00 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evotec currently has a consensus target price of $7.00, suggesting a potential upside of 160.22%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 15.34%. Given Evotec's stronger consensus rating and higher possible upside, equities analysts plainly believe Evotec is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Evotec has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

5.8% of Evotec shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Organon & Co. beats Evotec on 9 of the 14 factors compared between the two stocks.

How does Evotec compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NewAmsterdam Pharma currently has a consensus price target of $48.60, indicating a potential upside of 49.06%. Evotec has a consensus price target of $7.00, indicating a potential upside of 160.22%. Given Evotec's higher possible upside, analysts plainly believe Evotec is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

NewAmsterdam Pharma has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market. Comparatively, Evotec has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

In the previous week, Evotec had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 1 mentions for Evotec and 0 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.00 equaled Evotec'saverage media sentiment score.

Company	Overall Sentiment
NewAmsterdam Pharma	Neutral
Evotec	Neutral

Evotec has higher revenue and earnings than NewAmsterdam Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.57M	168.92	-$203.82M	-$1.79	N/A
Evotec	$891.97M	1.07	-$117.12M	N/A	N/A

Evotec has a net margin of -26.20% compared to NewAmsterdam Pharma's net margin of -943.23%. Evotec's return on equity of -24.93% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Evotec	-26.20%	-24.93%	-11.35%

Summary

Evotec beats NewAmsterdam Pharma on 8 of the 14 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVO vs. The Competition

Export

Metric	Evotec	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$956.99M	$3.00B	$6.56B	$12.24B
Dividend Yield	N/A	1.80%	2.69%	5.82%
P/E Ratio	N/A	18.63	25.14	23.99
Price / Sales	1.07	477.27	553.65	120.26
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	1.04	4.14	10.77	6.43
Net Income	-$117.12M	$64.45M	$3.56B	$337.14M
7 Day Performance	3.07%	1.26%	1.36%	-0.47%
1 Month Performance	-11.22%	0.88%	0.80%	0.50%
1 Year Performance	-34.07%	24.28%	30.54%	27.96%

Evotec Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVO Evotec	1.9476 of 5 stars	$2.69 +2.7%	$7.00 +160.2%	-31.2%	$956.99M	$891.97M	N/A	4,553
CPRX Catalyst Pharmaceuticals	2.9117 of 5 stars	$31.38 +0.0%	$32.00 +2.0%	+42.0%	$3.84B	$588.99M	18.03	80	News Coverage Positive News
CRNX Crinetics Pharmaceuticals	3.4055 of 5 stars	$34.61 -1.5%	$76.13 +120.0%	+20.1%	$3.66B	$7.70M	N/A	210
ACAD ACADIA Pharmaceuticals	4.1458 of 5 stars	$21.24 -0.1%	$31.63 +48.9%	+0.5%	$3.63B	$1.07B	9.63	510
OGN Organon & Co.	2.6714 of 5 stars	$13.45 +0.0%	$11.40 -15.2%	+37.0%	$3.53B	$6.22B	14.46	10,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVO) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evotec (EVO) Competitors

EVO vs. CPRX, CRNX, ACAD, OGN, and NAMS

How does Evotec compare to Catalyst Pharmaceuticals?

Summary

How does Evotec compare to Crinetics Pharmaceuticals?

Summary

How does Evotec compare to ACADIA Pharmaceuticals?

Summary

How does Evotec compare to Organon & Co.?

Summary

How does Evotec compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evotec (EVO) Competitors

EVO vs. CPRX, CRNX, ACAD, OGN, and NAMS

How does Evotec compare to Catalyst Pharmaceuticals?

Do insiders & institutionals have more ownership in CPRX or EVO?

Does the media refer more to CPRX or EVO?

Which has more volatility & risk, CPRX or EVO?

Is CPRX or EVO more profitable?

Which has preferable valuation & earnings, CPRX or EVO?

Do analysts rate CPRX or EVO?

Summary

How does Evotec compare to Crinetics Pharmaceuticals?

Do analysts prefer EVO or CRNX?

Is EVO or CRNX more profitable?

Which has better valuation and earnings, EVO or CRNX?

Which has more volatility & risk, EVO or CRNX?

Does the media refer more to EVO or CRNX?

Do institutionals & insiders have more ownership in EVO or CRNX?

Summary

How does Evotec compare to ACADIA Pharmaceuticals?

Is ACAD or EVO more profitable?

Do analysts recommend ACAD or EVO?

Which has more volatility and risk, ACAD or EVO?

Does the media favor ACAD or EVO?

Do insiders & institutionals hold more shares of ACAD or EVO?

Which has stronger earnings & valuation, ACAD or EVO?

Summary

How does Evotec compare to Organon & Co.?

Which has better valuation & earnings, EVO or OGN?

Is EVO or OGN more profitable?

Does the media refer more to EVO or OGN?

Do analysts rate EVO or OGN?

Which has more risk & volatility, EVO or OGN?

Do institutionals & insiders hold more shares of EVO or OGN?

Summary

How does Evotec compare to NewAmsterdam Pharma?

Do institutionals & insiders believe in NAMS or EVO?

Do analysts rate NAMS or EVO?

Which has more risk & volatility, NAMS or EVO?

Does the media prefer NAMS or EVO?

Which has stronger valuation & earnings, NAMS or EVO?

Is NAMS or EVO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools